Navigation Links
Vista Partners Updates Coverage on MediciNova Inc. (NASDAQ: MNOV); Maintains $8.50 Price Target
Date:10/21/2008

LOS ANGELES, Oct. 21 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on MediciNova Inc. (Nasdaq: MNOV) and maintains its $8.50 price. "MediciNova recently announced positive preliminary data on MN-221. MN-221, if approved, will garner a sizable percentage of the asthma market potentially resulting in hundreds of millions of dollars in sales for MediciNova. Medicinova's other clinical candidate, MN-166, is intended for the treatment of multiple sclerosis (MS) and MS is a multi-billion dollar market. As the Company announces additional positive data the value of Medicinova will increase," said Ross Silver, Director of Research for Vista Partners. For more information and to download the FREE report, please visit the Vista Partners website at http://www.vistap.com and click on the download research icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About MediciNova, Inc.:

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmace
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
2. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
6. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
7. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
8. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
9. Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
10. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
11. Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., Craig Moskowitz, a four...of Medicine, is choosing to go into internal medic... North Brunswick, NJ (PRWEB) December 1...cores on the US medical licensing examinations, Cr...ss University School of Medicine--knew he could go...
(Date:12/1/2009)..., Recent Reviews In Major... One Of The Most Promising New Developments For Th...tive Functioning Difficulties. Some Of The Most Re...(PRWEB) December 1, 2009 -- Review written by: Lee...sorders , Volume 13, No. 3 November 2009. A nice s...
(Date:12/1/2009)..., Anthony M. Marlon, MD w.... (“Stemedica”) Board of Directors at ..., (PRWEB) December 1, 2009...edica Cell Technologies , Inc. (“Stemedica&r...ovember 20th Board Meeting. Roger J. Howe, PhD, Ex...
(Date:12/1/2009)..., All Federal and Georgia... hearing aid benefits. This new benefit is part of...drugs (MAPD) private fee for service (PFFS) Option... Healthcare and Kaiser Permanente. Atlanta Hearing... in Dunwoody, GA Lake Oconee / Greensboro, GA and ...
(Date:12/1/2009)..., , EAGAN, Minn., Dec. 1 ...proach to health care for Blue Cross and Blue Shie...ers today, becoming the first Minnesotans - and th...o Online Care Anywhere(SM). Online Care Anywhere a... work simply by logging onto a computer or picking...
Breaking Medicine News(10 mins):Health News:Trending Against the Norm: How One Top Scoring Ross University Medical Student is Choosing to Make a Difference in Internal Medicine 2Health News:Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV 2Health News:Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV 3Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 2Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 3Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 2Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 3Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 4Health News:Blue Cross and Blue Shield of Minnesota and Fairview Health Services Launch Online Care Anywhere(TM) 2Health News:Blue Cross and Blue Shield of Minnesota and Fairview Health Services Launch Online Care Anywhere(TM) 3
...chers at the University of Pennsylvania School of ...ity have identified for the first time a specific ...timulating factor 1, Csf1, that has a direct effec...lated by the pituitary gland to supply testosteron...
... March 6 Alexza Pharmaceuticals, Inc. (Nasdaq: ...s for its fiscal year ended December 31, 2008, on ...e U.S. financial markets. The Company will host a...f the call will be available for two weeks followi...
... Supporters of the Glenda Dawson Donate Life - T...l at the Texas State Capitol on March 26, between ...onor registration process and getting them signed ... be in front of the Capitol Grill at the Texas St...
... The Crossings, the Texas Hill Country spa retrea...Day for each day booked. From March 8 until Apri...hree healthy gourmet meals, gracious and comfortab...finity pool, whirlpool, cold plunge, Watsu pool, s...
...h., March 6 Versus Technology,Inc. ("Versus" or t...venues of,$1,613,000 for the fiscal quarter ended ...$1,426,000 for the same period in 2008. The growt...nues can vary,significantly depending upon the tim...
...Health Care: Pharmacy and Other Services category;...ment worldwide , , FRANKLIN LAKES, N.J., March 6 ...ured the No. 1 position within the Health Care: Ph...d No. 5 in Innovation and No. 10 in People Managem...
Other Medicine News:Health News:Penn vet researchers identify a critical growth factor that stimulates sperm stem cells to thrive 2Health News:Penn vet researchers identify a critical growth factor that stimulates sperm stem cells to thrive 3Health News:Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009 2Health News:Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009 3Health News:Donate Life Day at the Capitol to Increase Awareness for Organ Donation and Registration 2Health News:Donate Life Day at the Capitol to Increase Awareness for Organ Donation and Registration 3Health News:Donate Life Day at the Capitol to Increase Awareness for Organ Donation and Registration 4Health News:A Massage A Day at The Crossings 2Health News:Versus Technology Announces First Quarter Results 2Health News:Versus Technology Announces First Quarter Results 3Health News:Versus Technology Announces First Quarter Results 4Health News:Versus Technology Announces First Quarter Results 5Health News:Versus Technology Announces First Quarter Results 6Health News:Medco Tops Fortune's Lists of 'World's Most Admired' Companies 2Health News:Medco Tops Fortune's Lists of 'World's Most Admired' Companies 3
(Date:11/30/2009)... , CHICAGO, Nov. 30 MedPro I...ultrasound solutions, will showcase leading ultras... Logiq I and Siemens X300 Premium Edition during t...f North America (RSNA) conference, being held in C...ased MedPro Imaging markets ultrasound products an...
(Date:11/30/2009)... , CHICAGO, Nov. 30 Minim...g more costly open surgery, particularly in oncolo...ith a global market for image-guided navigation ex...re embracing the advantages offered by minimally-i...very times, greater patient comfort and faster pat...
(Date:11/30/2009)... , WAYNE, N.J. and CHICAGO, Nov. 30 /PRNewswi...nnual Meeting of the Radiological Society of Nor...s Inc. announced the enrollment of the first patie... evaluate the efficacy and safety of florbetaben (...Amyloid plaques in the brain, which are a patholog...
Breaking Medicine Technology:MedPro Imaging to Showcase Leading New and Refurbished Ultrasound Solutions at RSNA 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 4Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 5Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 2Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 3DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 1DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 2DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 3DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 4DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 5Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 51043 1Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 51043 2Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 51043 3Breakfast Anyone 3F Lifestyle Foods Launches Two Energizing Snacks Containing Under 200 Calories 51041 1Breakfast Anyone 3F Lifestyle Foods Launches Two Energizing Snacks Containing Under 200 Calories 51041 2
...BRUNSWICK, N.J., May 7 Johnson & Johnson,will pro... on Friday, May 9,at 4:00 p.m. (Eastern Time) to c...ual meeting in Tampa, Fla. Phase 3 clinical data p...te release (IR), a novel centrally acting,oral ana...S., A pre-recorded Webcast, with the lead tapenta...
...-Large Study Shows Benefits Differ from those in A...n to,children who are hospitalized for bacterial m...in reduced hospital stays, according to a large,mu...ding stands in contrast,to previous studies in hos...cally reduced mortality., "Because of the demonst...
Other Medicine Technology:Steroids Provide No Survival Benefit for Children With Bacterial Meningitis 2Steroids Provide No Survival Benefit for Children With Bacterial Meningitis 3
Ultra Thin Sheet
Tanne Corneal Cutting Block
Surgical Markers
Periosteal Elevator
Medicine Products: